Accelerate projects by selecting reagents in 30 seconds vs 12 weeks
Reduce hard cost of consumables up to $6 million per year
Empower organizational purpose by restoring research time to scientists
See real business impact from AI with a proven, turnkey application
Backed by Google’s AI fund, Gradient Ventures, BenchSci is the industry standard for antibody selection.
Over 31,000 scientists in 15 of the top 20 pharmaceutical companies and 3,600 academic institutions use BenchSci’s AI-Assisted Antibody Selection to plan more successful experiments, with proven savings up to $2 million per year in hard costs alone. But antibodies constitute just 40-50% of reagent failures.
What began with antibody selection now encompasses all reagents, including:
Representing about 40-50% of reagent waste, with millions of products and hundreds of vendors
Often the second highest source of waste after antibodies, with a similar number of products and vendors
Challenging to search for, with many not cited by SKU, and a need to find through other means such as sequence
Fundamental to molecular biology experiments with many elements to consider when selecting
Critical tools whose common misidentification and misuse can have a devastating impact on research projects
One of the most important new gene editing technologies, with the need to select vectors, nuclease, guide RNA, screening libraries, and trans-activating RNA